Company Profile
Neumora Therapeutics Stock Price, News & Catalysts
- Ticker:
- NMRA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.63 USD (+7.59%)
Close
Last updated: August 21, 2026
324M USD
Market cap
Why the stock is moving
As of Aug 21, 2026, NMRA closed up 7.59% at $1.63. No new same-company headline was identified in the current news window.
Company overview
Novel-Mechanism Therapeutics
Neumora Therapeutics develops medicines targeting novel biological mechanisms across brain and centrally mediated diseases. Its current clinical and preclinical portfolio includes programs in neuropsychiatric disorders, neurodegeneration, obesity, and cardiometabolic disease.
NMRA-215
NMRA-215 is an NLRP3 inflammasome inhibitor being developed for obesity and cardiometabolic disease. The program is advancing toward first-in-human development after favorable preclinical findings.
NMRA-511
NMRA-511 is a vasopressin 1a receptor antagonist being developed for agitation associated with Alzheimer's disease. Neumora is evaluating higher doses in a multiple-ascending-dose expansion cohort involving healthy elderly participants before moving into a patient-based Phase 2 study.
NMRA-898
NMRA-898 is an M4 muscarinic receptor positive allosteric modulator being developed for schizophrenia. The ongoing Phase 1 multiple-ascending-dose study includes both healthy volunteers and patients with stable schizophrenia.
Future catalysts
- Phase 1 multiple-ascending-dose data for NMRA-898 in the second half of 2026.
- Submission of an IND for NMRA-215 in the fourth quarter of 2026.
- Multiple-ascending-dose expansion data for NMRA-511 in the fourth quarter of 2026.
- Initiation of the Phase 1 study of NMRA-215 by the end of 2026.
- Initiation of the Phase 2 study of NMRA-511 in Alzheimer's disease agitation by the end of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Neumora Therapeutics (NMRA)?
Neumora Therapeutics (NMRA) most recently closed at 1.63 USD, a +7.59% move versus the previous session.
What is the market cap of Neumora Therapeutics (NMRA)?
Neumora Therapeutics currently has a market capitalization of 324M USD on BioPharmSignal.
What does Neumora Therapeutics do?
Novel-Mechanism Therapeutics Neumora Therapeutics develops medicines targeting novel biological mechanisms across brain and centrally mediated diseases. Its current clinical and preclinical portfolio includes programs in neuropsychiatric disorders, neurodegeneration, obesity, and cardiometabolic disease. NMRA-215 NMRA-215 is an NLRP3 inflammasome inhibitor...
On which exchange is NMRA stock listed?
Neumora Therapeutics (NMRA) is associated with NASDAQ, United States, Biopharma.
What is NMRA-215?
Submission of an IND for NMRA-215 in the fourth quarter of 2026.
Which conditions is Neumora Therapeutics targeting with NMRA-215?
Neumora Therapeutics is associated with metabolic disease, obesity based on its company overview and current catalyst commentary.
How does Neumora Therapeutics describe recent progress with NMRA-215?
Submission of an IND for NMRA-215 in the fourth quarter of 2026.
What is NMRA-511?
NMRA-511 NMRA-511 is a vasopressin 1a receptor antagonist being developed for agitation associated with Alzheimer's disease.